| Diep N Truong, PHARMD | |
|
1485 Cuciz Ln, Milpitas, CA 95035-8203 | |
| (408) 476-9779 | |
| Not Available |
| Full Name | Diep N Truong |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1485 Cuciz Ln, Milpitas, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124563200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 56773 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Diep N Truong, PHARMD 1485 Cuciz Ln, Milpitas, CA 95035-8203 Ph: (408) 476-9779 | Diep N Truong, PHARMD 1485 Cuciz Ln, Milpitas, CA 95035-8203 Ph: (408) 476-9779 |
News Archive
Liberia was the epicenter of a high-profile Ebola outbreak in 2014-15, which led to more than 10,000 deaths in West Africa. But for all the devastation the illness caused, it could have been worse without an innovative, volunteer-based outreach program Liberia's government deployed in late 2014.
Adding to the clinical benefits and improved patient outcomes associated with minimally invasive surgery, Medtronic highlighted a study published in the March 25 online edition of JAMA Surgery. The new study demonstrated that patients who underwent laparoscopic colectomy procedures required fewer days of health care utilization and the health care system spent less on their acute and follow-up care than those who underwent traditional open surgery.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
Ms. Lisa Anani, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 45 N Milpitas Blvd, Milpitas, CA 95035 Phone: 408-946-6424 | |
Anne Chu, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 770 E Calaveras Blvd, Milpitas, CA 95035 Phone: 408-945-2645 Fax: 408-945-2038 | |
Jyoshna Kolisetty, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1102 S Abel St Apt 337, Milpitas, CA 95035 Phone: 475-225-0566 | |
Dr. Suneet Kaur Dhillon, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 270 Enriquez Ct, Milpitas, CA 95035 Phone: 408-726-4465 | |
Jessica Park, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1833 N Milpitas Blvd, Milpitas, CA 95035 Phone: 408-726-4657 | |
Anh Le, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 440 Dempsey Rd Unit 142, Milpitas, CA 95035 Phone: 415-912-0286 | |
Jade Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 611 S Milpitas Blvd, Milpitas, CA 95035 Phone: 408-945-2903 |